Xellia Pharmaceuticals expands Budapest facilities to strengthen anti-infective product capabilities
Foundation Stone Laying Ceremony of new $10 million Centralized Laboratory Services building attended by Deputy State Secretary Kristóf Altusz from the Hungarian Ministry of Foreign Affairs and Trade, and Mayor Mr Róbert Kovács
Xellia Pharmaceuticals has held an official ground breaking ceremony for a new $10million expansion of its Budapest manufacturing facility to include product stability and release testing capabilities.
The ceremony, which took place on Wednesday 25 May, was attended by local dignitaries including Deputy State Secretary Kristóf Altusz from the Hungarian Ministry of Foreign Affairs and Trade, the districts local Mayor Mr Róbert Kovács and the Danish Ambassador Tom Norring, celebrated the start of the construction of a new multi-story, 3,000 m2 Centralized Laboratory Services building.
The new facility is located next to Xellia’s APIs manufacturing plant, which currently has 200 employees. On completion in summer 2017, the building will house state-of-the-art microbiology and chemical analytical laboratories as well as administrative offices. The company also intends to extend its highly skilled team with up to 80 new roles in manufacturing, product testing and quality assurance.
The Centralized Laboratory Services building will play an important part in Xellia’s global operational strategy, strengthening its product release and stability testing services for Finished Dosage Form (FDF) and APIs produced across many of the Company’s other international sites.
Carl-Åke Carlsson, CEO, Xellia said; “It has been great to welcome Mayor Mr. Róbert Kovács to Xellia Budapest to officially break ground at our new site. With antimicrobial resistance posing a very real international threat, our work in the production of generic anti-infectives is especially important. As a world-leading supplier we are committed to providing the highest level of quality and compliance in the manufacture of our APIs and FDFs.”
“The Centralized Laboratory Services building will ensure that, as our global production volumes continue to increase in response to customer demand, we have the expertise and the capacity to continue to deliver effective and quality assured anti-infective products.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance